Who
Gary M. Phillips
Director
Company insider
Files Form 4 as: Director, Aldeyra Therapeutics; Director, Zyla Life Sciences; Exec. VP & Chief Strategy Ofcr, Mallinckrodt; Director, Rocket Pharmaceuticals; Vice President, Bausch & Lomb.
In numbers
- Trades disclosed
- 95
- Buys
- 2
- Sells
- 0
- Bought
- $147K
- Sold
- $0
- Companies
- 5
- Companies where not an officer
- 3
- First trade
- 15 Feb 2006
- Last trade
- 9 Jun 2026
- Last filed
- 11 Jun 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 9 Jun 2026filed 11 Jun 2026 | ALDX Aldeyra Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —70,000 at $0.00 | filing |
| 9 Jun 2026filed 11 Jun 2026 | ALDX Aldeyra Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —6,636 at $0.00 | filing |
| 9 Jun 2026filed 11 Jun 2026 | ALDX Aldeyra Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —4,977 at $0.00 | filing |
| 9 Jun 2026filed 11 Jun 2026 | ALDX Aldeyra Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —70,000 at $0.00 | filing |
| 9 Jun 2026filed 11 Jun 2026 | ALDX Aldeyra Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —6,636 at $0.00 | filing |
| 9 Jun 2026filed 11 Jun 2026 | ALDX Aldeyra Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —4,977 at $0.00 | filing |
| 10 Jun 2025filed 12 Jun 2025 | ALDX Aldeyra Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —62,728 at $0.00 | filing |
| 10 Jun 2025filed 12 Jun 2025 | ALDX Aldeyra Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —4,825 at $0.00 | filing |
| 10 Jun 2025filed 12 Jun 2025 | ALDX Aldeyra Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —3,619 at $0.00 | filing |
| 4 Jun 2024filed 6 Jun 2024 | ALDX Aldeyra Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —40,282 at $0.00 | filing |
| 4 Jun 2024filed 6 Jun 2024 | ALDX Aldeyra Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —3,473 at $0.00 | filing |
| 4 Jun 2024filed 6 Jun 2024 | ALDX Aldeyra Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —2,604 at $0.00 | filing |
| 7 Sep 2023filed 11 Sep 2023 | ALDX Aldeyra Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —5,437 at $0.00 | filing |
| 7 Sep 2023filed 11 Sep 2023 | ALDX Aldeyra TherapeuticsBiotechnology | SEC FORM 4 Code M | $2,9905,437 at $0.55 | filing |
| 30 Jun 2023filed 5 Jul 2023 | ALDX Aldeyra Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —21,222 at $0.00 | filing |
| 30 Jun 2023filed 5 Jul 2023 | ALDX Aldeyra Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —1,829 at $0.00 | filing |
| 30 Jun 2023filed 5 Jul 2023 | ALDX Aldeyra Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —1,372 at $0.00 | filing |
| 7 Jun 2022filed 9 Jun 2022 | ALDX Aldeyra Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —53,812 at $0.00 | filing |
| 7 Jun 2022filed 9 Jun 2022 | ALDX Aldeyra Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —4,639 at $0.00 | filing |
| 7 Jun 2022filed 9 Jun 2022 | ALDX Aldeyra Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —3,479 at $0.00 | filing |
News
No headline names them, or the companies they trade most, lately.